Geron Corp (GERN) @ NASDAQ
Printed Friday, 15 May '26 16:17 MST
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Biotechnology Pharmaceuticals, Biotechnology & Life Sciences Common Stock β +0.681
| Date | Name (*Public) | Description | Symbol | Type | Size | Action |
|---|
| Date | Value | Error | Logarithmic | Error | Model (*Public) |
|---|
-$0.11 (7.86%) on Friday, 15 May 2026, Marketcap $827.56 M
| Date | Value | Δ | Open | Close | Low | High | Adjusted | Volume | Δ |
|---|
| Name | Version (*Public) | Indicator % | Auto | Description | Symbol | Company Name | Forecasts | Buy / Sell | Action |
|---|
| Opened (Closed) | Expires | Symbol | Company Name | Name (*Public) | Size | Contract Symbol | Open P/L | Close P/L | Total P/L | ROI | DTE | DIT | Delta | Action |
|---|
| Details | Best Trend by Hindsight | Forecast | Profit or Loss | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Date (*Public) | Symbol | Strategy | Data | Origin | Slope | Sigma | Cor % | Moves | Sigma | Moves | Gain % | Periods | Action |
| Date | Name (*Public) | Description | Price | Quantity | Total | Cost | Type | Symbol | Action |
|---|
| Date | RSI | Stochastic %D | Stochastic %K | MACD | MACD Divergence | MACD Signal | DMI | CCI | Volatility | Bollinger Upper | Bollinger Mid | Bollinger Lower |
|---|
| Date | Name | Description | Type | Symbol | Company Name | Location |
|---|
| Date UTC | Location | Action | Description | Object | Severity | User | Action |
|---|
